SBI Mutual Fund reduced its stake in Archean Chemical Industries to 4.34% following a market sale of 1,47,599 shares on September 3, 2026.

The mutual fund reported the change in shareholding under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure was filed on September 4, 2026.

Transaction Details

Prior to the sale, SBI Mutual Fund held 55,11,173 shares, representing 4.4640% of the company’s paid-up equity capital. The disposal of 1,47,599 shares, equivalent to 0.1196% of the total share capital, brought the final holding down to 53,63,574 shares.

The transaction was executed through an open market sale. There were no changes in voting rights other than those carried by the shares, nor any encumbrances or convertible securities involved in the transaction.

Shareholding Structure

Archean Chemical Industries has a total paid-up equity capital of ₹24,69,16,788, consisting of 12,34,58,394 equity shares with a face value of ₹2 each. This capital structure remained unchanged following the transaction.

Archean Chemical Industries reported a significant turnaround in its consolidated profit after tax (PAT) for Q1FY27, which more than doubled to ₹303.5 million from ₹122.3 million in the preceding quarter. The strong bottom-line performance was underpinned by an 11% year-on-year rise in total revenue to ₹3,328 million and a 48.5% sequential jump in consolidated EBITDA to ₹728.7 million. This improvement marks the company’s highest quarterly revenue in five quarters, driven primarily by robust demand in the Bromine segment and operational efficiencies in its derivatives business, despite persistent logistical headwinds in the core Industrial Salt division.

Financial Performance Highlights

On a standalone basis, Archean Chemical’s total income reached ₹3,321 million, up 14% year-on-year and 9% sequentially. Standalone EBITDA expanded by 26.3% sequentially to ₹838.7 million (corrected from initial report of ₹888.7 million), with margins improving from 21.8% in Q4FY26 to 25.3% in Q1FY27. Standalone PAT rose 36% sequentially to ₹405.3 million.

Consolidated metrics reflected the strength of the standalone business, although results were partially offset by scaling costs in newer ventures like the semiconductor unit. Consolidated EBITDA stood at ₹728.7 million, while consolidated PAT was ₹303.5 million. Basic EPS for the quarter was ₹2.48.

Note: S = Standalone, C = Consolidated. Errata corrected per management call.

Segment Drivers and Operational Updates

The Bromine segment remained the primary growth engine, delivering revenue of ₹1,333 million, up 58% year-on-year, on volumes of 4,175 tons. Managing Director Rampraveen Swaminathan noted that bromine realizations were up 50% year-on-year and are expected to remain firm near the ₹300 per kg level. Volumes were slightly below the potential run rate due to grid power shortages and planned maintenance for debottlenecking, which impacted production by approximately three days.

In contrast, the Industrial Salt segment faced continued pressures, with revenue declining 12% year-on-year to ₹1,713 million on volumes of 982,000 tons. Logistics costs surged due to higher diesel prices (up ~60% year-on-year during April–June) and increased freight distances caused by ongoing highway construction near the Hajipur plant. Sea freight costs also rose by 30–35%, impacting landed costs for exports to East and South Asia. Management expects salt volumes and profitability to normalize from Q3FY27 as infrastructure works complete by September.

A key strategic milestone was achieved by Acume Chemicals, the bromine derivatives arm, which turned EBITDA-positive for the first time. Acume reported an EBITDA of ₹19 million against a loss of ₹27 million in Q1FY26, driven by improved capacity utilization (~40%) and a shift toward higher-value organic derivatives like NPBR. Revenue for this segment grew 28% to approximately ₹300 million.

Strategic Initiatives and Outlook

Archean is advancing several long-term projects. SiCSem Private Limited, the semiconductor venture, has entered the execution phase following the Fiscal Support Agreement signed with the Government of India on May 11. Construction is scheduled to begin in late August or early September 2026, with commercial start-of-production targeted within 24–27 months. Capex for the project is estimated at $249 million, with 60–65% expected to be incurred in FY27.

In energy storage, Offgrid Energy Labs inaugurated a 10 MWh Zinc Bromide battery pilot facility in the UK. This initiative aims to create pull-through demand for Archean’s zinc bromide products, with plans for future gigafactory-scale projects in India contingent on pilot success.

What the Numbers Show

The divergence between the Industrial Salt and Bromine segments highlights Archean’s successful pivot toward higher-margin chemical specialties. While the traditional salt business remains cyclical and sensitive to logistics shocks, the Bromine and Derivatives segments are demonstrating structural resilience and margin expansion. The turnaround in Acume Chemicals’ EBITDA signals that capacity utilization improvements are yielding tangible financial results, reducing reliance on the core salt business for profitability. However, near-term net profit growth will depend on the normalization of logistics costs in H2FY27 and the sustained firmness of bromine realizations amid global supply normalization.